XM levert geen diensten aan inwoners van de Verenigde Staten.
S
S

Sanofi


Nieuws

Sanofi India June-Quarter Consol Profit 1.03 Billion Rupees

BRIEF-Sanofi India June-Quarter Consol Profit 1.03 Billion Rupees July 26 (Reuters) - Sanofi India Ltd SANO.NS : JUNE-QUARTER CONSOL PROFIT 1.03 BILLION RUPEES JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.64 BILLION RUPEES Source text for Eikon: ID:nBSE558tlQ Further company coverage: SANO.NS
S

Sanofi SA reports results for the quarter ended in January - Earnings Summary

Sanofi SA reports results for the quarter ended in January - Earnings Summary Sanofi SA SNY.OQ reported quarterly adjusted earnings of 93 cents​​ per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of 95 cents. The lone analyst forecast for the quarter was for earnings of 86 cents per share.
S

European shares fall as earnings deluge disappoints

UPDATE 2-European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast Besi tumbles as Q3 outlook disappoints Unilever gains after H1 profit beat Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan July 25 (Reuters) - European shares closed lower on Thursday as a slate of downbeat earnings reports in several sectors including tech and luxury weighed, while a global run for safe haven
K
L
N
R
R
S
A
E
F
U
G

STOXX 600 drops to 12-week low as earnings fail to impress

LIVE MARKETS-STOXX 600 drops to 12-week low as earnings fail to impress STOXX 600 down 1.2% CAC 40 hits lowest since Jan UMG tumbles after results European semis weak Healthcare shines Wall St futures steady Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com STOXX 600 DROPS TO 12-WEEK LOW AS EARNINGS FAIL TO IMPRESS European equities are in the red on Thursday as the decline in glob
A
R
S
V
E
F
U
G

Sanofi up as Dupixent boosts Q2 and prompts 2024 outlook hike

BUZZ-Sanofi up as Dupixent boosts Q2 and prompts 2024 outlook hike ** Shares in Sanofi SASY.PA rise 2.5% as the French pharma giant raises full-year profit guidance after Q2 was boosted by its blockbuster asthma drug Dupixent ** It now sees stable 2024 business EPS vs 2023, up from a previous forecast for it to drop in a low single-digit percentage
J
S

Global equity slump set to gather momentum in Europe

LIVE MARKETS-Global equity slump set to gather momentum in Europe Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com GLOBAL EQUITY SLUMP SET TO GATHER MOMENTUM IN EUROPE The global equity retreat that has gripped markets looks set to continue in Europe on Thursday, with futures signalling a firmly negative open.
A
K
R
S
E
F
U
G

Sanofi lifts 2024 profit forecast on strength in Dupixent, new products

UPDATE 2-Sanofi lifts 2024 profit forecast on strength in Dupixent, new products Adds share movement and analyst comment in paragraph 3, background on Roche and AstraZeneca in paragraph 4 By Manas Mishra July 25 (Reuters) - Sanofi SASY.PA on Thursday raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected sales of new launches helped its second-quarter results beat estimates.
A
R
S

Stock rout spreads beyond tech

LIVE MARKETS-Stock rout spreads beyond tech Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com STOCK ROUT SPREADS BEYOND TECH The global equity sell-off looks set to extend into Europe on Thursday although the region may be spared the carnage in parts of Asia, where Japan's Nikkei .N225 tumbled as much as 3% and Hong Kong's Hang Seng .HSI slumped close to 2%.
A
G
H
K
L
N
S
T
U
J
E
F
U
G

Sanofi CFO says no decision made on consumer health separation

Sanofi CFO says no decision made on consumer health separation July 25 (Reuters) - Sanofi's SASY.PA CFO Francois-Xavier Roger said on Thursday that the company was reviewing potential scenarios for the separation of its consumer health unit, including a sale or a listing, but no decision has been made. The French drugmaker expects to make a decisio
S

Sanofi Eyes Stable Y/Y FY Business EPS At Constant FX

BRIEF-Sanofi Eyes Stable Y/Y FY Business EPS At Constant FX July 25 (Reuters) - Sanofi SA SASY.PA : Q2 GROSS PROFIT EUR 7.97 BILLION VERSUS VARA CONSENSUS EUR 7.73 BILLION Q2 NET SALES EUR 10.74 BILLION VERSUS VARA CONSENSUS EUR 10.40 BILLION Q2 SG AND A EXPENSES EUR 2.66 BILLION VERSUS VARA CONSENSUS EUR 2.62 BILLION Q2 BUSINESS EPS EUR 1.73 VERSU
S

Sanofi bumps up full-year forecast after strong Q2 profit

Sanofi bumps up full-year forecast after strong Q2 profit July 25 (Reuters) - Sanofi's SASY.PA second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year profit compared to a prior forecast of a fall. Operating income, excluding one-off items, rose 3.2% to 2.81 billion euros ($3.05 billion), above the 2.08 billion euros expected on average by analysts in a poll on the
A
R
S

Roche lifts 2024 profit guidance on strong drug sales

UPDATE 2-Roche lifts 2024 profit guidance on strong drug sales First-half operating profit growth beats analyst estimates Revenue from eye drug Vabysmo nearly doubles, beats estimates Expects close to 10% adjusted profit growth, up vs previous Shares traded near 1-year high earlier on Thursday Adds details on eye drug in paragraphs 5 and 7, details on CEO's strategy in last two paragraphs By Ludwig Burger FRANKFURT, July 25 (Reuters) - Roche ROG.S on Thursday raised its full-year earnings foreca
A
B
R
R
S

Stock rout spreads beyond tech

REFILE-MORNING BID EUROPE-Stock rout spreads beyond tech Corrects story links, no changes to text A look at the day ahead in European and global markets from Kevin Buckland The global equity sell-off looks set to extend into Europe on Thursday although the region may be spared the carnage in parts of Asia, where Japan's Nikkei .N225 tumbled as much as 3% and Hong Kong's Hang Seng .HSI slumped close to 2%.
A
E
H
K
L
N
S
T
U
U
U

Merck's RSV shot helps protect infants in mid-to-late stage study

UPDATE 3-Merck's RSV shot helps protect infants in mid-to-late stage study Adds analyst comment in paragraph 3 By Vaibhav Sadhamta July 23 (Reuters) - Merck's MRK.N antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV), the company said on Tuesday.
A
P
S

Sanofi SA <SNY.OQ> expected to post earnings of 86 cents a share - Earnings Preview

Sanofi SA expected to post earnings of 86 cents a share - Earnings Preview Sanofi SA SNY.OQ , SNY.O is expected to show a rise in quarterly revenue when it reports results on July 25 for the period ending June 30 2024 The Paris Ile-de-france-based company is expected to report a 3.6% increase in revenue to $11.239 billion from $10.85 billion a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
S

Drug giants eye China for deals despite growing Sino-US tensions

ANALYSIS-Drug giants eye China for deals despite growing Sino-US tensions Bristol Myers Squibb, Sanofi looking at China M&A -employees AstraZeneca, Novartis have done China deals this year Political risks are a consideration -analysts By Andrew Silver and Kane Wu SHANGHAI/HONG KONG, July 23 (Reuters) - Some of the biggest global drugmakers, undeterred by mounting Sino-U.S.
A
N
S

Rentokil flags debugged trend towards mega buyouts

BREAKINGVIEWS-Rentokil flags debugged trend towards mega buyouts The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Updates to add graphic. By Karen Kwok LONDON, July 22 (Reuters Breakingviews) - A potential takeover of London-listed rat-catcher Rentokil RTO.L is a sign that mega buyouts are getting debugged. Former BT BT.L boss Philip Jansen is talking to private equity groups about taking the $17 billion company private, says the Sunday Times.
B
R
S
F
R

EU's Borrell to discuss security, climate policy with Vietnam next week

EU's Borrell to discuss security, climate policy with Vietnam next week By Francesco Guarascio HANOI, July 22 (Reuters) - European Union foreign policy chief Josep Borrell will visit Vietnam next week to discuss how to boost cooperation with the Southeast Asian country in areas including security and sustainable development, the EU ambassador in Hanoi said.
A
S

France corporate earnings week ahead

DIARY-France corporate earnings week ahead July 19 (Reuters) - Diary of France (.FCHI) corporate earnings for the week ahead FRANCE EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 23-Jul-2024 AMC LVMH.PA LVMH Moet Hennessy Louis Vuitton SE Half Year 2024 LVMH Moet Hennessy Louis Vuitton SE Earnings Release 23-Jul-2024 BMO EDEN.PA Edenred SE Half Year 2024 Edenred SE Earnings Release 23-Jul-2024 05:00 TCFP.PA Thales SA Half Year 2024 Thales SA Earnings Release 24-Jul-2024 AMC CAR
A
B
B
C
C
D
E
E
H
K
L
O
R
S
T
V
V
A
F

Sanofi's Consumer Arm Said To Draw Bids From Advent, Pai, CD&R ; Bids Value Business At Up To Eur 15 Bln - Bloomberg News

BRIEF-Sanofi's Consumer Arm Said To Draw Bids From Advent, Pai, CD&R ; Bids Value Business At Up To Eur 15 Bln - Bloomberg News July 17 (Reuters) - Sanofi SA SASY.PA : SANOFI’S CONSUMER ARM SAID TO DRAW BIDS FROM ADVENT, PAI, CD&R ; BIDS VALUE BUSINESS AT UP TO EUR 15 BILLION - BLOOMBERG NEWS Source : https://tinyurl.com/3ntmm7cu
S



Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.